For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Century Therapeutics Inc (NASDAQ: IPSC) was $0.56 for the day, up 6.20% from the previous closing price of $0.53. In other words, the price has increased by $6.20 from its previous closing price. On the day, 0.63 million shares were traded. IPSC stock price reached its highest trading level at $0.5699 during the session, while it also had its lowest trading level at $0.53.
Ratios:
Our analysis of IPSC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.70 and its Current Ratio is at 11.70. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on August 08, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On August 28, 2023, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $28 to $5.
On December 27, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $19.Chardan Capital Markets initiated its Buy rating on December 27, 2022, with a $19 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 09 ’25 when Carr Douglas sold 4,904 shares for $0.62 per share. The transaction valued at 3,050 led to the insider holds 405,982 shares of the business.
Farid Adrienne sold 552 shares of IPSC for $343 on Jun 09 ’25. The Chief Operations Officer now owns 250,141 shares after completing the transaction at $0.62 per share. On Jun 09 ’25, another insider, Pfeiffenberger Brent, who serves as the President and CEO of the company, sold 475 shares for $0.62 each. As a result, the insider received 295 and left with 1,681,783 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IPSC now has a Market Capitalization of 48671104 and an Enterprise Value of -63774916. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42 while its Price-to-Book (P/B) ratio in mrq is 0.20. Its current Enterprise Value per Revenue stands at -0.555 whereas that against EBITDA is 3.893.
Stock Price History:
The Beta on a monthly basis for IPSC is 1.77, which has changed by -0.6843575 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, IPSC has reached a high of $2.16, while it has fallen to a 52-week low of $0.34. The 50-Day Moving Average of the stock is -2.69%, while the 200-Day Moving Average is calculated to be -31.29%.
Shares Statistics:
IPSC traded an average of 966.70K shares per day over the past three months and 1220500 shares per day over the past ten days. A total of 86.15M shares are outstanding, with a floating share count of 52.20M. Insiders hold about 39.41% of the company’s shares, while institutions hold 29.48% stake in the company. Shares short for IPSC as of 1752537600 were 1393002 with a Short Ratio of 1.44, compared to 1749772800 on 2316058. Therefore, it implies a Short% of Shares Outstanding of 1393002 and a Short% of Float of 2.41.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 3.0 analysts currently analyzing and rating the stock of Century Therapeutics Inc (IPSC).The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.37 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.24 and -$0.36 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$1.68, with 3.0 analysts recommending between -$1.54 and -$1.79.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for IPSC’s current fiscal year. The highest revenue estimate was $109.2M, while the lowest revenue estimate was $109.16M, resulting in an average revenue estimate of $109.19M. In the same quarter a year ago, actual revenue was $6.59M
